Antibodies against 6-sulfo-LacNac-positive human dendritic cells, and their use
    1.
    发明授权
    Antibodies against 6-sulfo-LacNac-positive human dendritic cells, and their use 有权
    针对6-磺基-LacNac阳性人树突状细胞的抗体及其用途

    公开(公告)号:US09487585B2

    公开(公告)日:2016-11-08

    申请号:US13814512

    申请日:2011-08-05

    摘要: The invention relates to a composition which contains at least one anti-slan antibody and to its diagnostic and therapeutic use. The composition according to the invention comprises: a) at least one anti-slan antibody, b) at least one binding unit which binds to a co-stimulus binding to a co-stimulus-specific receptor on dendritic cells, thereby bringing about the modulation, preferably the activation, of said dendritic cells, and c) at least one antigen. The invention furthermore comprises anti-slan antibodies which include CDRs with the following sequences: variable region of the heavy chain: CDR1 (SEQ ID No. 1), CDR2 (SEQ ID No. 2), where Xaa is selected from among M, L, F, or I, preferably from among M or I, CDR3 (SEQ ID No. 5) and variable region of the light chain: CDR1 (SEQ ID No. 6), where Xaa is selected from among S, T, N, Q, H, K or R, preferably from among S or N, CDR2 (SEQ ID No. 9) and CDR3 (SEQ ID No. 10).

    摘要翻译: 本发明涉及含有至少一种抗唾液酸抗体及其诊断和治疗用途的组合物。 根据本发明的组合物包含:a)至少一种抗蝙蝠抗体,b)至少一个结合单元,其结合共刺激与树突状细胞上的共刺激特异性受体的结合,由此引起调节 ,优选活化所述树突状细胞,和c)至少一种抗原。 本发明还包括抗an抗体,其包括具有以下序列的CDR:重链可变区:CDR1(SEQ ID No.1),CDR2(SEQ ID No.2),其中Xaa选自M,L ,F或I,优选M或I,CDR3(SEQ ID No.5)和轻链可变区:CDR1(SEQ ID No.6),其中Xaa选自S,T,N, Q,H,K或R,优选来自S或N,CDR2(SEQ ID No.9)和CDR3(SEQ ID No.10)。